Search company, investor...

Regado Biosciences

Founded Year



IPO | Merged

Total Raised






About Regado Biosciences

Regado Biosciences, a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. The Company provides REG1 that is used in patients suffering from acute coronary syndrome that undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention.

Headquarters Location

120 Mountainview Blvd.

Basking Ridge, New Jersey, 07920,

United States


Missing: Regado Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Regado Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Regado Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Regado Biosciences is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Regado Biosciences Patents

Regado Biosciences has filed 9 patents.

patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Coagulation system, Coagulopathies, Glycoproteins, Proteins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Coagulation system, Coagulopathies, Glycoproteins, Proteins



Latest Regado Biosciences News

DiNAQOR Appoints Two Seasoned Executives to Leadership Team

Jan 9, 2023

News provided by Share this article Share this article Chris Rusconi to serve as Chief Development Officer; Steven Zelenkofske to take role of Chief Strategy Officer as DiNAQOR continues rapid growth SCHLIEREN, Switzerland, Jan. 9, 2023 /PRNewswire/ -- DiNAQOR , a genetic medicine platform company, today announced that it has added to its leadership team with the appointments of two veteran biotechnology executives. Chris Rusconi, Ph.D. , who brings decades of experience in global pharmaceutical development, will serve as DiNAQOR's Chief Development Officer. , an expert in clinical development and adaptive trial design and operations who serves on DiNAQOR's board of directors, will assume the role of Chief Strategy Officer. "We are fortunate to add Chris and Steve's expertise to DiNAQOR's leadership at such a pivotal time for our company," said Johannes Holzmeister, M.D., Chairman and CEO of DiNAQOR. "In addition to the progress we are making on our pipeline of genetic medicines, we are operating a robust technology platform and a manufacturing subsidiary to help other biotech companies bring their innovations to market. Their industry experience will be invaluable to us as we continue to push forward on behalf of patients." Dr. Rusconi, an expert in leveraging platform science to create product pipelines, brings to his new role more than 20 years of biotech executive experience with both privately held and publicly traded companies and extensive global pharmaceutical development and regulatory experience. He comes to DiNAQOR from the PKD Foundation, a not-for-profit organization dedicated to finding treatments and a cure for polycystic kidney disease (PKD). He also served as the Chief Scientific Officer at Vitrisa Therapeutics, the founding CEO of Ribometrix, and was a co-founder and Chief Scientific Officer at Regado Biosciences. Prior to Regado he served as Director of Research for the Program in Combinatorial Therapeutics and as an Assistant Research Professor of Surgery at Duke University Medical Center. "Taking on a leadership role with DiNAQOR is an exciting opportunity and the beginning of a new chapter for me," Dr. Rusconi said. "The company's platform capabilities make it a true outlier in genetic medicine, and I look forward to helping the company stay on the leading edge as it grows rapidly." Dr. Zelenkofske, who will continue to serve on DiNAQOR's board of directors, assumes the role of Chief Strategy Officer with more than 20 years of biopharmaceutical, medical device, and gene therapy industry experience and more than a decade of cardiovascular academic and clinical experience. He has been responsible for multiple NDA filings and approvals throughout his career and has held leadership positions at SwanBio Therapeutics, Achillion Pharmaceuticals, uniQure, Regado Biosciences, AstraZeneca, Sanofi-Aventis, and Boston Scientific. His work has spanned numerous therapeutic areas including neurology, immunology, hematology, cardiovascular, metabolic diseases, diabetes, and nephrology. "I have been with DiNAQOR as a director throughout this exciting growth phase, and I look forward to taking on new responsibilities as we continue our trajectory," Dr. Zelenkofske said. "Patients are waiting for new treatment options, and we are committed to finding solutions for these individuals and their families." About DiNAQOR DiNAQOR is a genetic medicine platform company pioneering early-stage drug development and manufacturing to advance promising gene therapies to the clinic. The company's patent-protected, industry leading platform is designed to overcome the challenges and limitations of advanced gene therapy development by using proprietary engineered heart tissue technology (EHT), a novel Loco-Regional Perfusion system (LRP) and a fully integrated manufacturing solution. The company is headquartered in Zurich-Schlieren, Switzerland, with additional presence in Hamburg, Germany and Laguna Hills, California. For more information visit . Contact

Regado Biosciences Frequently Asked Questions (FAQ)

  • When was Regado Biosciences founded?

    Regado Biosciences was founded in 2003.

  • Where is Regado Biosciences's headquarters?

    Regado Biosciences's headquarters is located at 120 Mountainview Blvd., Basking Ridge.

  • What is Regado Biosciences's latest funding round?

    Regado Biosciences's latest funding round is IPO.

  • How much did Regado Biosciences raise?

    Regado Biosciences raised a total of $173.63M.

  • Who are the investors of Regado Biosciences?

    Investors of Regado Biosciences include Aurora Funds, Quaker BioVentures, Domain Associates, Andera Partners, Caxton Advantage Life Sciences Fund and 8 more.

  • Who are Regado Biosciences's competitors?

    Competitors of Regado Biosciences include Portola Pharmaceuticals, Threshold Pharmaceuticals, Dendreon, Decimmune Therapeutics, REGiMMUNE and 14 more.

Compare Regado Biosciences to Competitors

Altair Therapeutics

Altair Therapeutics is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions.

SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

Chroma Therapeutics

Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.

Iconic Therapeutics

Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific knowledge into new medicines. The company's understanding of the role of the tissue factor in angiogenesis, inflammation, and malignancies has led it to a new approach to developing therapies for devastating diseases such as macular degeneration and cancer.

Alice Therapeutics

Alice Therapeutics is a biotechnology company.


REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.